KaydedilenlerDerginizi ekleyin

Dergiler / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2012 / Cilt: 25 - Sayı: 2

Eroin bağımlılığının tedavisinde buprenorfin

Buprenorphine in The Treatment of Heroin Addiction

James BELL
Sayfa
93–100
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

BELL, J. (2022). Eroin bağımlılığının tedavisinde buprenorfin. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 25 - Sayı: 2, 93–100. https://ajindex.com/articles/493743

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. United Nations Office on Drugs and Crime. World Drug Report. New York, USA: United Nation, 2007
  2. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna-Taglianti F, Faggiano F, VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102:1954-1959
  3. Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94:221-229
  4. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97: 1383-1394
  5. Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend 2005; 78:73-81
  6. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269:1953-1959
  7. Hser Y, Hoffman V, Grella C, Anglin MD. A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001; 58:503-508
  8. Volkow ND, Li TK. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther 2005; 108:3-17
  9. Holmstrand J, Anggard E, Gunne LM. Methadone maintenance: Plasma levels and therapeutic outcome. Clin Pharmacol Ther 1978; 23:175-180
  10. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65:685-694
  11. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98:673-684
  12. Milby JB. Methadone maintenance to abstinence: how many make it? J Nerv Ment Dis 1988; 176:409-422
  13. McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100: 447-458
  14. Fudala PJ, Jaffe JH, Dax E, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioural effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47; 525-534
  15. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: Single and conti